Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries Ltd. (TEVA) Q2 EarningsZacks Investment Research • 08/02/23
Teva Takes A Run At Its 200-Day Line After Second-Quarter Beat And RaiseInvestors Business Daily • 08/02/23
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business DevelopmentBusiness Wire • 07/27/23
Teva Pharmaceuticals upgraded with improving product mix set to bolster gross marginsProactive Investors • 07/06/23
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023Business Wire • 07/05/23
Teva's 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraineBusiness Wire • 06/30/23
Teva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in PatientsBusiness Wire • 06/15/23
Teva Reaches Agreement With Kentucky to Settle the State's Price Fixing ClaimsBusiness Wire • 06/12/23
Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend ItWSJ • 06/09/23
NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's AllerganMarket Watch • 06/09/23
Teva concludes nationwide opioid settlement agreement, reaches separate settlement with NevadaMarket Watch • 06/08/23
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma ManagementBusiness Wire • 06/06/23